Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome
Status:
Unknown status
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
To evaluate safety and efficacy of 3-day cetrotide therapy started on day of oocyte retrieval
(Day-0) in women at high-risk for development of ovarian hyperstimulation syndrome (OHSS)
after gonadotropin- releasing hormon agonist induction protocol.
Patients & Methods: Forty-eight women fulfilling inclusion criteria underwent ultrasound
scanning for maximal ovarian diameter (MOD) estimation and ascites grading. Patients
underwent embryo freezing, but study group received 3-day Cetrotide sc injection (0.25
mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value
(Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading
were re-evaluated on Day-3, 6 and 8